Affordable Access

A clinical comparison between non-specific cross-reacting antigen and CEA in patient's sera.

British Journal of Cancer
Nature Publishing Group
Publication Date
  • Research Article
  • Biology
  • Chemistry
  • Medicine


Br. J. Cancer (1977) 35 875. Short Communication A CLINICAL COMPARISON BETWEEN NON-SPECIFIC CROSS-REACTING ANTIGEN AND CEA IN PATIENTS' SERA S. VON KLEIST, S. TROUPEL, M. KING AND P. BURTIN From the Laboratoire d'Immunochimie, Institut de Recherches Scientifiques sur le Cancer, 94800 Villejuif, France Received 4 June 1976 NUMEROUS antigens have been des- cribed to date that were claimed to cross- react with the carcinoembryonic antigen of the digestive tract (CEA) discovered by Gold and Freedman (1965). Among them, only one has been sufficiently purified and characterized to allow further, more detailed studies of its immunological relationship with CEA, its identity with other cross-reacting substances, and its possible clinical value. This antigen has been given 4 different names. NCA (for " non-specific cross- reacting antigen ") is our name for it (von Kleist, Chavanel and Burtin, 1972) and other names are NGP (for " normal glycoprotein ") favoured by Mach and Pusztaszeri (1972), CCA III by Newman et al., (1972) and CE-X by Darcy, Turber- ville and James (1973), who showed the immunological identity of 3 of these antigens (NCA, NGP and CE-X). NCA is one of the 3 principal colonic carcinoma antigens regularly present in perchloric-acid extracts of these and other tumours and normal tissues, and a ten- acious contaminant of CEA preparations (von Kleist et al., 1972; von Kleist, 1973). There exist many physico-chemical simi- larities between the two antigens; they differ from each other, however, in molecu- lar weight and by the unshared antigenic determinants on their respective mole- cules. This permits their separation and specific detection in tissues and body fluids. Accepted 14 February 1977 NCA being closely related to CEA in both reactivity and cellular distribution, we wanted to know whether it might have a similar oncological relevance to CEA. Little is yet known (and even less pub- lished) of the clinical value of this antigen, especially in regard to cancer. This stu

There are no comments yet on this publication. Be the first to share your thoughts.